The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | TRANSCEND-CLL-004: pivotal in the FDA approval of liso-cel for R/R CLL
Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the TRANSCEND-CLL-004 trial (NCT03331198), pivotal in the FDA approval of lisocabtagene maraleucel (liso-cel) for relapsed/refractory chronic lymphocytic leukemia (CLL). The trial included heavily pretreated patients; among those previously exposed to both BTK inhibitors and venetoclax, there was a 20% complete remission (CR) rate and 44% overall response rate (ORR). Safety outcomes for cytokine release syndrome (CRS) and neurotoxicity were mostly non-high grade, consistent with liso-cel’s profile in other indications. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Juno therapeutics, AbbVie, Kite Pharma, Celgene, BeiGene, AstraZeneca, BMS
Research Funding: Juno therapeutics, TG therapeutics, Oncternal, Pharmacyclics, LLC an AbbVie Company, Ascentage Pharma, Kite Pharma, Celgene, BeiGene, AstraZeneca
Speakers Bureau: Janssen, BeiGene, AstraZeneca, BMS
Board of Directors/Advisory Committee: AbbVie, Kite Pharma, Celgene, BeiGene, AstraZeneca, BMS
